Skip to main content

Table 2 Meta-analysis of FXBW7 status and clinicopathological features in CRC

From: Clinical significance of FBXW7 tumor suppressor gene mutations and expression in human colorectal cancer: a systemic review and meta-analysis

Parameters Characteristics Number of studies OR (95%CI) I2 (%) Ph Z P value
Age(≥ 60 year vs. <  60 year) 3 1.00 (0.93–1.36) 0 0.71 0.00 1.00
Gender (Male vs. Female) 7 1.03 (0.83–1.28) 6 0.38 0.28 0.78
Differentiation(Well vs. Moderate + Poor) 2 0.81 (0.40–1.64) 0 0.63 0.89 0.37
Differentiation(Well+ Moderate vs. Poor) 4 0.72 (0.35–1.48) 69 0.02 0.59 0.55
Size(≥ 5 cm vs. <  5 cm) 3 0.93 (0.64–1.35) 0 0.45 0.37 0.71
Tumor location(Colon vs. Rectum) 5 0.85 (0.64–1.12) 30 0.22 1.17 0.24
Venous invasion(Present vs. Absent) 3 1.63 (1.01–2.64) 14 0.31 1.99 0.05
Peritoneal metastasis (Present vs. Absent) 2 0.82 (0.38–1.80) 0 0.40 0.49 0.63
Depth of invasion (T1 + T2 vs. T3 + T4) 3 0.44 (0.27–0.74) 0 0.99 3.12 <  0.01
Lymph node metastasis (Positive vs. Negative) 5 1.88 (1.40–2.53) 0 0.45 4.18 <  0.01
Distant metastasis (Present vs. Absent) 3 1.85 (0.34–10.24) 92 <  0.01 0.71 0.48
TNM stage(I + II vs. III + IV) 3 0.53 (0.15–1.84) 95 <  0.01 1.00 0.32
Duke’s stage(A + B vs. C + D) 2 0.45 (0.04–5.20) 90 <  0.01 0.64 0.52